

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

December 18, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/420,065

FILING DATE: *October 21, 2002*

RELATED PCT APPLICATION NUMBER: PCT/US03/33354

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*M. Sias*  
M. SIAS  
Certifying Officer

RECEIVED	
29 DEC 2003	
WIPO	PCT

PRIORITY DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

*102-2* 60420065 - 102102  
**PROVISIONAL APPLICATION COVER SHEET**

This is a cover sheet for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

EXPRESS MAIL LABEL INFO:  
L928557898US

DATE OF DEPOSIT: October 21, 2002



L 928557898US

Docket Number:

PRI-0002 / PRD0054

Type a plus sign  
(+) inside this  
box--

10879 U.S. PRO  
60420065  
10/21/02



10/21/02

**INVENTOR(S)/APPLICANT(S)**

GIVEN NAME (FIRST AND MIDDLE [IF ANY])	FAMILY NAME OR SURNAME	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
Ann Sandy Curt	Barbier Wilson Mazur	La Jolla, California San Diego, California San Diego, California

Additional inventors are being named on the \_\_\_\_\_ separately numbered sheets attached hereto

**TITLE OF THE INVENTION (280 characters max)**

**ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE**

**CORRESPONDENCE ADDRESS**

Scott E. Scioli  
WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone (215) 568-3100  
Facsimile (215) 568-3439

**ENCLOSED APPLICATION PARTS (check all that apply)**

<input checked="" type="checkbox"/> Specification	Number of Pages <u>40</u>	<input checked="" type="checkbox"/> Claims (optional)
<input checked="" type="checkbox"/> Drawing(s)	Number of Sheets <u>4</u>	<input checked="" type="checkbox"/> Other (specify) <u>Sequence Listing pgs 1-14</u>

**METHOD OF PAYMENT (check one)**

A check or money order is enclosed to cover the Provisional filing fee:

\$80.00 Small Entity  
 \$160.00 Large Entity

The Commissioner is hereby authorized to charge filing fee and credit Deposit Account Number: 23-3050

The Commissioner is hereby authorized to charge Deposit Account 23-3050 any fee deficiency or credit account for any overpayment.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Scott E. Scioli

Date: October 21, 2002  
REGISTRATION NO. 47,930  
(if appropriate)

**PROVISIONAL APPLICATION FILING ONLY**

## Assay for Determining the Activity of Fatty Acid Amide Hydrolase

### Field of the Invention

[0001] The present invention relates to methods for determining the activity of and identifying modulators of fatty acid amide hydrolases. More specifically, the invention relates to an assay, adaptable for high throughput screening, for compounds that alter fatty acid amide hydrolase activity.

### Background

[0002] The identification of anandamide (N-arachidonylethanolamine, AEA) as an endogenous ligand for the cannabinoid 1 receptor (Devane *et al.* (1992) *Science* 258:1946-1949) evoked much scientific interest in the function of bioactive lipids. Other examples of endogenous ligands are oleamide (*cis*-9,10-octadecenoamide), best known for its sleep-inducing properties (Cravatt *et al.* (1995) *Science* 268:1506-1509), and 2-arachidonoylglycerol, reported to be neuroprotective after brain injury (Panikashvili *et al.* (2001) *Nature* 413:527-531).

[0003] The main mechanism for the termination of the biological activity of anandamide is hydrolysis (Giuffrida *et al.* (2001) *J. Pharmacol. Expt. Ther.* 298:7-14); the existence of an anandamide transporter has also been proposed (Compton and Martin (1997) *J. Pharmacol. Expt. Ther.* 263:1138-1143).

[0004] The enzyme responsible for the hydrolysis of anandamide, deamide and 2-arachidonoylglycerol was cloned in 1996 and named fatty acid amide hydrolase or FAAH (Cravatt *et al.* (1996) *Nature* 384:87-87). FAAH (EC 3.5.1.4) is a membrane-bound enzyme with broad substrate specificity which is expressed in a wide variety of

PRI-0002

human tissues and cell lines (for review see Ueda *et al.*, *Chem.Phys.Lipids.* 108: 107-121, (2000); Fowler *et al.*, *Biochem. Pharmacol.* 62: 517-526, (2001).

[0005] Inhibitors of FAAH have been predicted to potentiate the effects of the endogenous cannabinoids and thereby promote sleep, muscle relaxation and analgesia (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526). Efforts to identify useful inhibitors have been hampered by the lack of simple, reproducible assays suitable for high-throughput screening. Published methods include reversed phase HPLC (9) and thin-layer chromatography (Deutsch and Chin (1993) *Biochem. Pharmacol.* 46:791-796). A fluorescence displacement method has also been described (Thumser *et al.* (1997) *Biochem. Pharmacol.* 53:433-437). An additional assay relies on extraction of the hydrolysis product with a chloroform: methanol mixture (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86), followed by counting of radioactivity. However, the toxicity of the chloroform and the cumbersome physical manipulations of this method preclude the adaptation of this assay to a high-throughput format.

[0006] There is a need in the art, therefore, for improved FAAH assays, particularly those which can be adapted to high throughput screening, for determining the activity of FAAH and for identifying modulators of FAAH.

#### **SUMMARY OF THE INVENTION**

[0007] In one aspect, the instant invention provides methods for assaying the activity and amount of fatty acid amide hydrolase (FAAH) based on differences in the physicochemical and binding properties of a FAAH substrate, and the products of its hydrolysis. For example, anandamide is hydrolyzed by FAAH to arachidonic acid and ethanolamine (Fig. 1). In brief, a substrate, for example  $^3\text{H}$ -anandamide (ethanolamine 1- $^3\text{H}$ ), is incubated with a putative source of FAAH activity in a

reaction mixture. The FAAH activity, where present, catalyzes the hydrolysis of the substrate to form at least one radiolabeled hydrolysis product; the example substrate <sup>3</sup>H-anandamide is converted to labeled ethanolamine and unlabeled arachidonic acid. This labeled product and the labeled substrate are separated from each other and the loss of labeled substrate, or preferably, the formation of labeled product, is measured. In certain preferred embodiments, the assays are performed in parallel or in sets wherein assays conducted in the presence of compounds to be tested for their ability to modulate the FAAH activity are compared with those conducted in the absence of the compounds to be tested. In other preferred embodiments samples from patients can be assayed to determine if the FAAH activity is altered relative to a predetermined activity value.

[0008] In one aspect, the invention provides improved methods of measuring fatty acid amide hydrolase activity comprising combining a sample suspected of containing fatty acid amide hydrolase, with a labeled substrate of fatty acid amide hydrolase to form a reaction mixture; incubating the reaction mixture under conditions which allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material wherein the selective binding material binds either the labeled substrate or the labeled product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining the amount of labeled substrate hydrolyzed or the amount of labeled hydrolysis product formed; thereby indicating the fatty acid amide hydrolase activity of the sample. The assay methods provided are adaptable for use in

high throughput screening systems and are contemplated to be used in drug discovery efforts.

[0009] In another aspect of the invention, methods are provided for identifying compounds which can modulate the activity of a FAAH enzyme. The methods comprise the steps of comparing the activity of a FAAH as assayed by the above method in the presence and in the absence of a test compound added to the reaction mixture; wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase. In various embodiments, the methods can be used to identify useful inhibitors or enhancers of FAAH activity. High throughput screening using the assay methods of the present invention will allow libraries of test compounds (for example, libraries produced by techniques of combinatorial chemistry) to be used in rational screening programs to identify inhibitors and enhancers of FAAH activity which are useful as candidates for drugs

[0010] In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled

complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

[0011] These and other aspects of the present invention will be described in further detail in the Detailed Description set forth below.

[0012] **BRIEF DESCRIPTION OF THE FIGURES**

[0013] **Figure 1:** Schematic diagram of a FAAH assay. The FAAH activity in T84 membranes converts anandamide [ $1-^3\text{H}$ -ethanolamine] into radiolabeled ethanolamine and unlabeled arachidonic acid. The labeled anandamide and unlabeled arachidonic acid are selectively bound to charcoal in filterplates, whereas the radiolabeled ethanolamine is collected in the flow-through and counted.

[0014] **Figure 2** depicts an embodiment of a FAAH assay method. The reaction takes place in a reaction plate at room temperature. After 60 minutes, 60  $\mu\text{l}$  of the reaction mixture is transferred to a charcoal-filled filter plate. The filter plate is fitted on top of a Dynex plate; the assembly is then centrifuged for 5 minutes at 2000 rpm.

[0015] **Figure 3:** Arachidonic acid and anandamide, but not ethanolamine, bind to activated charcoal. Four different radiolabeled tracers were used: anandamide [ $1-^3\text{H}$ -ethanolamine], anandamide [arachidonyl-5,6,8,9,11,12,14,15- $^3\text{H}$ ], arachidonic acid [5,6,8,9,11,12,14,15- $^3\text{H}$  (N)] and ethanolamine ([ $2-^{14}\text{C}$ ] ethan-1-ol-2-amine hydrochloride). The tracers were incubated with membranes prepared from mouse

liver, T84 cells, HeLa cells or with vehicle, for 60 minutes at room temperature. The percentage (average of triplicate determinations  $\pm$  s.e.m.) of total radioactivity recovered in the flow-through is shown.

[0016] Figures 4A-4B: Characterization of a preferred assay. A: Time-course of hydrolysis of  $^3$ H-anandamide by FAAH at room temperature and at 37°C. The average of triplicate determinations  $\pm$  s.e.m. is shown. B: Determination of  $K_m$  for FAAH. T84 cell membranes (3.5  $\mu$ g protein per well) were incubated with a range of concentrations of  $^3$ H-anandamide. The reactions were carried out at room temperature in the presence or absence of inhibitors (either oleyl trimethylfluoro ketone or MAFP). The experiment where oleyl trimethylfluoro ketone was used to determine nonspecific binding is shown; the results with MAFP were comparable. Each point reflects the average of triplicate determinations  $\pm$  s.e.m.

[0017] DETAILED DESCRIPTION OF THE INVENTION

[0018] The reference works, patents, patent applications, and scientific literature, including accession numbers to GenBank database sequences, that are referred to herein are hereby incorporated by reference in their entireties.

[0019] Various definitions are made throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words specifically defined either below or elsewhere in this document have the meaning provided in the context of the present invention as a whole and as are typically understood by those skilled in the art. Any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

[0020] Standard reference works setting forth the general principles of recombinant DNA technology known to those of skill in the art include Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (2002); Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Plainview, New York (2001); Kaufman *et al.*, *Eds.*, *Handbook of Molecular and Cellular Methods in Biology and Medicine*, CRC Press, Boca Raton (1995).

[0021] As used herein, a "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes and fluorescent labels. Examples of radioisotopes that may be used in the method of the invention include  $^3\text{H}$  and  $^{14}\text{C}$ .

[0022] As used herein, "purified" refers to at least partial separation of a molecule from other molecules with which it is normally associated. For example, a purified protein is a protein that is at least partially separated from other cellular material with which it is normally associated.

[0023] As used herein, the term "murine" means originating in a member of the family *Muridae*. A murine FAAH preferably originates in a mouse, or rat.

[0024] In a first aspect the invention provides methods of assaying a fatty acid amide hydrolase (FAAH). In a presently preferred embodiment, the method of assay comprises the steps of combining a sample suspected of containing a FAAH with a labeled substrate of FAAH to form a reaction; incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, forming one or more labeled hydrolysis products; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not

both, to form a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.

[0025] The sample, in preferred embodiments, is a biological sample, or a sample comprising biological material, in particular biological membranes. In other preferred embodiments, the sample is from a purification step in the purification of FAAH from a biological source. The sample comprises biological membranes or portions thereof, or comprises lipid bilayers, or artificial membrane systems, monolayers, vesicles or micelles. A sample in some embodiments comprises a purified or recombinant FAAH reconstituted into a phospholipid-containing reaction mixture.

[0026] The substrate may be any substrate, putative substrate, or substrate analog of FAAH. The assay is also adapted for use to determine the utility of a compound as a substrate of FAAH. Substrates preferred for use in various embodiments of the present invention include, but are not limited to endocannabinoids or analogs thereof, fatty acid ethanolamides or analogs thereof, fatty acid primary amides or analogs thereof, and analogs of any of the foregoing labeled with a detectable label. Presently preferred substrates of particular interest include, for example, anandamide, oleamide, and 2-arachidonoylglycerol.

[0027] The substrate may be radioisotopically labeled in any manner known in the art for labeling compounds for detection. Presently preferred isotopes, such as <sup>3</sup>H or <sup>14</sup>C, are readily detected via liquid scintillation counting and can facilitate adaptation of the assays for high throughput drug screening. Synthetic substrates so labeled are readily available commercially or can be synthesized.

[0028] Other labels such as fluorescent labels capable of detection, for example fluorimetric detection, are also readily adapted to high throughput screening. Preferred fluorescent labels are detectable in biological systems with both proteins and nucleic acids present, therefore preferred labels when assaying cruder cell lysates and homogenates possess both excitation and emission optima which are not masked by these other biological components. In one embodiment the unhydrolyzed labeled substrate has identical fluorescent properties with the hydrolysis product. It is also possible to design substrates wherein hydrolysis results in a change in fluorescence, for example, where a dye-dye interaction in the unhydrolyzed molecule is required to maintain a ground state. Such substrates are useful in conjunction with the present invention. Colorimetric labels are also contemplated for use herein. Generally, appropriate labels are those which do not alter the substrate's susceptibility to hydrolysis by the enzyme and for which detection systems have been developed.

[0029] Preferably the substrate is present at concentrations at vast excess relative to the concentration of the enzyme. Under such conditions classical enzyme kinetics can be used to determine a rate constant ( $K_m$ ) and a velocity ( $V_{max}$ ) of the reaction. Kinetic studies are useful for mechanistic studies; they are also powerful tools for evaluating inhibitors (see below). Standard texts directed at those skilled in the art of enzyme kinetics such as Segel, I.H., *Enzyme Kinetics : Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems* (1993, Wiley-Interscience, ISBN 0471303097) provide complete guidance to establishing these parameters and demonstrate the use, for example, of Lineweaver-Burke plots as graphical tools to simplify the determination of the kinetic parameters.

[0030] High throughput screening systems are known in the art. Such systems often involve the use of multiwell plates to increase the number of assays conducted

simultaneously from a few to a hundred, a few hundred or even a few thousand.

Presently preferred high throughput screening adaptions of the methods of the present invention provide capability of screening about one hundred to about one or more thousand assays in a short time. Presently preferred high throughput screening systems include robotic components for example for sample handling, dispensing, reagent addition, and other functions to improve accuracy and eliminate the labor intensive aspects of large numbers of assays. Detection systems for high throughput screening programs are known to those of ordinary skill in the art. Preferred detection systems include, but are not limited to, scintillation counting (including, for example, solid and liquid scintillation for counting gamma or beta particles, or luminescent samples, filter counting, Cerenkov counting, and scintillating microplate counting), fluorescence detection (including, for example, intensity, fluorescence polarization, time-resolved fluorescence, fluorescence resonance energy transfer (FRET)), luminescence, and absorbance.

[0031] In a presently preferred embodiment, to achieve high-throughput screening, samples are placed on a multicontainer carrier or platform. A multicontainer carrier facilitates measuring reactions of a plurality of candidate compounds simultaneously. For illustration purposes, but not by way of limitation, a multi-well microplate, such as a 96 or a 384 well microplate, that can accommodate 96 or 384 different test reactions, is used as the carrier. Such multi-well microplates, and methods for their use in numerous assays, are both known in the art and commercially available through sources such as Sigma Chemical Co., BIOCHEMICAL ORGANIC COMPOUND AND DIAGNOSTIC REAGENTS, 2002, pages 2495-2511.

[0032] The methods of the present invention are adaptable to miniaturization techniques. Assays for purposes of high throughput screening are often conducted in

small volumes. Procedures are currently known to those of skill in the art of reducing volumes of assays in a variety of ways. Microfluidics and microcapillary methodologies now enable assays to be performed down to nanoliter quantities. It is to be understood that the basic principles of the methods and assays apply notwithstanding the volume of the assay, or the manner in which the materials are measured or transported.

[0033] The process of determining incubation conditions is routine in the art. Preferred incubation conditions relate, for example, to enzyme stability. Temperature optimums are routine to determine given the specification of the assay and should be determined for a given enzyme and substrate combination for optimum results. Times and other conditions for incubation involve likewise routine determinations. Preference is given to those conditions which result in linearity of the assay. Presently preferred temperatures and times include room temperature for 1 hour, or 37 °C for 30 min, using FAAH from a variety of sources and using anadamide as a substrate. Standard texts directed at those skilled in the art of enzyme assays such as Segel, *supra*, provide complete guidance to optimizing assays, including the incubation conditions. Further characterization of the preferred embodiments is provided in the working examples.

[0034] The methods also comprise a step wherein the incubated reaction mixture is contacted with a selective binding material. It is important to note that the selective binding material preferred for this assay may vary with the substrate selected. The selective binding materials comprise materials which can readily be separated from the bulk reaction mixture by separation techniques which are known in the art. Effective separations can be based on differences in particle size, density, composition and magnetic susceptibility. Material is separated from a reaction

mixture by, for example, gravity settling, filtration (including, for example, membrane separations), centrifugation. A presently preferred method of contacting the incubated reaction mixture with a selective binding material comprises activated charcoal.

[0035] Where the substrate is anandamide, for example, activated charcoal binds, through adsorption, the substrate and one of the hydrolysis products, arachidonic acid. The other hydrolysis product, ethanolamine, does not adsorb to the activated charcoal. For preferred embodiments, the anandamide substrate is labeled on the ethanolamine moiety. The FAAH hydrolyzes the labeled anandamide into labeled ethanolamine and unlabeled arachidonic acid. After adsorption of the labeled substrate and the unlabeled arachidonic acid to the charcoal, the labeled ethanolamine in solution can be separated from the bound labeled substrate through a simple filtration step. This facilitates the measurement of product without interference from substrate. By removing some compounds through the binding process, the sample is less likely to interfere, for example by quenching, with the measurement of the labeled product. Existing technology has already been adapted for filtering large numbers of samples simultaneously, for example in multiwell filters. This attribute also is adaptable therefore to high throughput screening programs.

[0036] Although it is often preferred to measure the formation of product in the methods of this invention, assay conditions and selective binding material may be selected wherein the disappearance of substrate is measured. This indirect method is adaptable particularly where a partially purified or substantially purified enzyme is used, or where it is known that there is only one route by which substrate disappears from the reaction mixture. It is also preferred to measure substrate disappearance wherein a selective binding material which binds the substrate is not readily available. This can be useful in particular in embodiments where the substrate cannot

practically be bound to effect its separation from free hydrolysis product but where the hydrolysis product can be more readily bound to effectively separate it from the free labeled substrate. This gives a practitioner the flexibility to choose from a broader range of selective binding materials.

[0037] The determination of the amount of labeled substrate hydrolyzed or the labeled hydrolysis product formed is preferably a direct method of quantitating the amount of label present. As discussed above, a variety of detection techniques are suitable for the present invention, and an appropriate detection method relates to the properties of the label present on the substrate or the product. Presently preferred for use with the methods of the invention are radioisotopically labeled substrates and fluorescently labeled substrates, quantified respectively by scintillation counting and fluorescence detection, respectively. In one preferred embodiment, the substrate is  $^3\text{H}$ -anandamide, the detection is of the product,  $^3\text{H}$ -ethanolamine, formed, and the detection is with a liquid scintillation counting plate reader from the filtrate of an assay conducted in a multiwell plate.

[0038] In another aspect of the invention, methods are provided for identifying modulators of fatty acid amide hydrolase. The methods comprise comparing the activity of fatty acid amide hydrolase as assayed by the method as described herein above, in the presence and in the absence of a test compound added to the reaction mixture; a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.

[0039] In preferred embodiments, the modulator to be identified is part of compound library, for example, a library of compounds formed by combinatorial chemistry, or a library of related compounds identified or synthesized as part of a research program. The putative modulators (i.e the compounds to be tested, test

compounds) are preferably a small molecule with properties that would allow it to have utility for pharmaceutical compositions. Preferred modulators have low nonspecific toxicity, and high specificity for modulating FAAH.

[0040] Modulators include inhibitors of FAAH activity and activators of FAAH. Assay parameters such as concentration of substrate, incubation conditions, and concentration of compounds to be tested may be varied to more fully appreciate the modulation effects of a test compound.

[0041] Preferred modulators that are inhibitors can be identified by their ability to decrease the activity of FAAH relative to that of a control reaction mixture lacking the test compound. Preferably, reaction volumes are maintained constant by adjusting the volume to compensate for the addition of a test compound where the addition of a test compound alters the reaction volume. Most preferably any difference in volume is compensated for by a corresponding addition of a volume, equal to the difference, of the vehicle in which the test compounds are dissolved.

[0042] In one aspect of the invention, the modulator identified is an inhibitor of the FAAH activity. Enzyme inhibitors include reversible and irreversible inhibitors. Preferred inhibitors in some embodiments are reversible inhibitors. Reversible inhibitors of FAAH include competitive inhibitors, which raise the apparent  $K_m$  of the reaction, noncompetitive inhibitors, which reduce the  $V_{max}$  of the enzyme, and inhibitors which affect both  $K_m$  and  $V_{max}$ , namely, mixed inhibitors and uncompetitive inhibitors. The type of inhibitor identified in screens can be determined through the use of kinetic assay studies according to the methods of the present invention. For the purposes of the present invention, however, any compound which decreases the apparent activity of the enzyme is considered a modulator of the inhibitor type. In

other preferred embodiments inhibiting modulators include irreversible inhibitors as well as noncompetitive inhibitors, whose action may be irreversible.

[0043] In preferred embodiments the test compound inhibits the FAAH reproducibly, as determined by a statistically significant difference by an appropriate statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, the test compound inhibits fatty acid amide hydrolase activity about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or about 95% or more, or up to 100%. In other preferred embodiments, the inhibitor statistically significantly increases the apparent  $K_m$  or decreases the  $V_{max}$  of the reaction.

[0044] In another aspect of the invention, the test compound increases fatty acid amide hydrolase activity. Various types of enzyme activators are known to those of skill in the art. Some activators are known to activate enzyme reactions by increasing the velocity of the reaction, others are known to alter the equilibrium attained. Activators that combine reversibly with enzyme reaction components (for example, the enzyme, the substrate, or enzyme-substrate or enzyme-product intermediates) to increase the velocity of the reaction are presently preferred. Nonspecific activators may also increase the reaction rate. For purposes of the present invention, any compound that increases the apparent activity of the enzyme is considered a modulator of the activator type. For example many enzymes are known to have increased activity in the presence of certain anions. Other enzymes, in particular those acting on water-insoluble and charge-neutral molecules, are activated by negatively charged lipophilic molecules. Some membrane bound enzymes are known to be activated, for example, by specific phospholipids.

PRI-0002

[0045] In preferred embodiments the test compound activates the FAAH reproducibly, as determined by a statistically significant difference by an appropriate statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, fatty acid amide hydrolase activity is increased about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or about 95% or more, or up to 100%. In other embodiments, activation is 10-30%, 30-50%, 50-70%, 70-90%, 90-110%. In some embodiments, the activator increases FAAH activity 100-300%, 300-500%, 500-700%, or 700-900% or more.

[0046] In certain preferred embodiments of the methods of the invention, the fatty acid amide hydrolase is a crude cell lysate or a cell homogenate. In some embodiments the FAAH is isolated partially or substantially from cells. In other embodiments, the fatty acid amide hydrolase is recombinantly produced. The fatty acid amide hydrolase may be from any biological source including mammalian fatty acid amide hydrolases from such animals as pigs, rodents (including rats and mice), and humans, or it may be recombinant FAAH produced in any organism known to be useful for the production of recombinant proteins. Synthetic FAAH based on a particular known amino acid sequence, or on a consensus or combination of any number of sequences that result in an active FAAH is also contemplated for use herein.

[0047] Examples of known amino acid sequences of fatty acid amide hydrolases from various biological sources include, for example, SEQ ID NOS: 2, 4, 6, and 8. Examples of known nucleic acid sequences encoding fatty acid amide hydrolases include SEQ ID NOS: 1, 3, 5 and 7. Persons of ordinary skill in the art will recognize that such sequences and the modifications thereof which retain activity, can be used in

accordance with the techniques found in references such as those provided above to generate, for example, biological FAAH, recombinant FAAH, overproduced FAAH, or genetically modified FAAH. It is contemplated herein that any form of FAAH is adapted for assay with the methods of the present invention.

[0048] In a preferred embodiment the assay is used to measure the activity and identify modulators of FAAH with altered amino acid sequences. Such altered FAAH can result from mutations in the genes which encode FAAH enzymes. In one embodiment, the assay is used to study the activity of, and identify modulators of, altered FAAH in connection with cannabis abuse. For example, a recent paper by Sipe *et al.* (PNAS 99:8394-8398, 2002) describes a strong association between the substitution of Thr for Pro at position 129, and substance abuse in humans. The use of the assay of the present invention may help identify FAAH from humans with higher specific activities or higher levels of net activity, thereby resulting in reduced concentrations of endocannabinoids in the brain, thereby leading to a tendency to seek external cannabinoids to compensate.

[0049] In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled

complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

[0050] Preferably, the fatty acid amide hydrolase activity from a sample of fluid or tissue originating from the patient is measured. Presently preferred are blood, lymph or tissue samples. In particularly preferred embodiments, the sample is from lymphocytes from the patient. In preferred embodiments, where the sample is from a woman, the results enable a physician to screen pregnant women for risk of miscarriage (spontaneous abortion) or to screen women seeking fertility treatment for risk of failure of *in vitro* fertilization procedures. In preferred embodiments, results from the patient's sample are compared to results from samples of normal individuals, particularly those comparably positioned in terms of demographic criteria. Results of the assays of the present method may be used to determine either or both of altered specific activity (FAAH activity per unit of FAAH mass) or altered total FAAH activity (net amount of product formed per time). For example, increases in activity can be due to increases in specific activity of the FAAH, for example by alteration of the active site via amino acid alteration, gene mutation and the like, or through alteration of the total amount of FAAH protein present, without a change in the specific activity.

[0051] In the methods of the invention, the fatty acid amide hydrolase may be substantially purified from the lymphocyte cell lysate. FAAH may be derived from

any source, such that the FAAH retains the potential for FAAH activity. For example, FAAH may be purified from cells expressing FAAH, FAAH may be produced in a recombinant system, including, but not limited to bacterial cells, yeast cells, insect cells, and mammalian cells. FAAH may be derived from any organism that produces FAAH. For example, FAAH may be derived from mammalian cells such as human cells, rodent cells (e.g., mouse and rat cells), or from any other organism that produces FAAH that has FAAH activity. Recombinant FAAH may be produced using techniques known in the art with any nucleic acid sequence encoding FAAH. Examples of cloned FAAHs include various mammalian FAAH such as, pig FAAH, rodent FAAH (e.g., mouse FAAH and rat FAAH), and human FAAH. DNA sequences encoding FAAH and polypeptide sequences of various FAAHs are included in the appended Sequence Listing.

[0052] FAAH may be purified by standard methods in the art. The FAAH preparation may be in association with cell membranes or artificial membranes, or may be substantially free of cellular material.

[0053] Throughout the specification, reference is made to certain publications and patents. The entireties of each of these references is incorporated herein and forms a part of this disclosure.

**[0054] EXAMPLES**

**[0055] Example 1**

[0056] Radiolabeled anandamide [1-<sup>3</sup>H-ethanolamine] was obtained from American Radiolabeled Chemicals (10-20 Ci/mmol, catalog number ARC-626; St.

originally done at 37°C for 30 min; but subsequent experiments indicated that the enzyme displayed good activity at room temperature, and experiments were performed at room temperature for 60 minutes unless otherwise indicated.

[0059] During the one hour incubation, 96-well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, Massachusetts, USA) were loaded with 25  $\mu$ l activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100  $\mu$ l methanol. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100  $\mu$ l MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, Connecticut, USA). After the one hour incubation, 60  $\mu$ l of the reaction mix was transferred to the charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2,000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at room temperature for 1 hour before counting on a Hewlett Packard TopCount. For determination of  $K_m$  values, 1  $\mu$ M  $^3$ H-AEA was combined with 30  $\mu$ M unlabeled AEA and serial 2-fold dilutions were made.

[0060] Uncleaved  $^3$ H-anandamide, as well as the unlabeled arachidonic acid, is absorbed by the charcoal. In contrast, the labeled  $^3$ H- ethanolamine flows through the charcoal mini-columns into 96 well counting plates when a vacuum or centrifugation is applied. The 96 well plates can then be read on a Hewlett Packard TopCount (Fig.2.)

[0061] *Charcoal selectively binds anandamide and arachidonic acid, but not ethanolamine:*

originally done at 37°C for 30 min; but subsequent experiments indicated that the enzyme displayed good activity at room temperature, and experiments were performed at room temperature for 60 minutes unless otherwise indicated.

[0059] During the one hour incubation, 96-well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, Massachusetts, USA) were loaded with 25  $\mu$ l activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100  $\mu$ l methanol. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100  $\mu$ l MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, Connecticut, USA). After the one hour incubation, 60  $\mu$ l of the reaction mix was transferred to the charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2,000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at room temperature for 1 hour before counting on a Hewlett Packard TopCount. For determination of  $K_m$  values, 1  $\mu$ M  $^3$ H-AEA was combined with 30  $\mu$ M unlabeled AEA and serial 2-fold dilutions were made.

[0060] Uncleaved  $^3$ H-anandamide, as well as the unlabeled arachidonic acid, is absorbed by the charcoal. In contrast, the labeled  $^3$ H- ethanolamine flows through the charcoal mini-columns into 96 well counting plates when a vacuum or centrifugation is applied. The 96 well plates can then be read on a Hewlett Packard TopCount (Fig.2.)

[0061] *Charcoal selectively binds anandamide and arachidonic acid, but not ethanolamine:*

[0062] Four different radioactive tracers were used to explore the binding characteristics of the charcoal used in the assay: two tritiated forms of anandamide (labeled either on the ethanolamine moiety; anandamide [1-<sup>3</sup>H-ethanolamine], or on the arachidonic acid moiety; arachidonic acid [5,6,8,9,11,12,14,15-<sup>3</sup>H (N)] ), as well as tritiated arachidonic acid, and <sup>14</sup>C-labeled ethanolamine. Specific amounts of these tracers were incubated with membrane preparations, added to the pre-washed charcoal and recovered by centrifugation, as described in the methods. The recovered radioactivity was counted and expressed as percentage of the amount added. As shown in Fig. 3, when no membranes were present, *i.e.*, there was no FAAH-mediated conversion of anandamide to arachidonic acid plus ethanolamine, neither of the two labeled forms of anandamide could be detected in the flow-through, indicating that the tracers were bound to the charcoal. Tritiated arachidonic acid was also absorbed onto the charcoal and could not be detected in the flowthrough. Of the four tracers used, only the <sup>14</sup>C-ethanolamine could be recovered.

[0063] It is known that HeLa cells, a human carcinoma cell line, do not express FAAH (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). Therefore, this cell line was used as a negative control, and to investigate the possible contribution of non-FAAH enzymes to the hydrolysis of anandamide. There was essentially no recovery of radioactivity after incubation of <sup>3</sup>H-anandamide with HeLa cell membranes, confirming the absence of FAAH (Fig. 3).

[0064] When the tracers were incubated with membranes prepared from mouse liver or T84 cells, good recovery of radioactivity was found for the anandamide labeled on the N-terminus of the amide (<sup>3</sup>H-ethanolamine), but not for the anandamide carrying the tritium label on the hydrocarbon chain of the fatty acid (<sup>3</sup>H-AA). All experiments consistently showed that anandamide and arachidonic acid, in

contrast to ethanolamine, were absorbed onto the charcoal column. Therefore, when radiolabeled anandamide is incubated with a cell lysate containing FAAH the radioactivity recovered in the flow-through must be attributed to the radiolabeled ethanolamine. This experiment indicates that it is possible to separate anandamide and ethanolamine using charcoal. Other products, such as SAX and C18 resin were also tested, but were less effective (not shown).

[0065] *Characterization of the FAAH assay:*

[0066] FAAH activity is found in a large variety of cells. In rodents, the liver, followed by the brain, seems to have the highest expression of FAAH, whereas in humans, the expression is highest in the pancreas and brain, but lower in the liver (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). The expression of human FAAH mRNA in T84 cells was found by expression profiling using DNA microarrays (not shown) and confirmed by subsequent experiments.

[0067] The signal output of the assay was determined to be linear in the range of 0.42-3.5  $\mu$ g/well T84 membrane. Since an embodiment of the invention is a HTS-compatible assay, it was verified that the reaction was linear over more than 1 hour at the amount of protein used. As shown in Figure 4 A, the rate of the reaction at room temperature was linear over a period of 90 minutes when 3.5  $\mu$ g/well protein was used. This experiment was performed both at room temperature and at 37°C, with the enzyme being slightly more active at the higher temperature, as expected. For the performance of HTS assays, an incubation period of 1 hour at room temperature and a protein amount of 3.5  $\mu$ g/ well was chosen based on these results.

[0068] *Kinetic analysis of FAAH activity:*

[0069] Kinetic analyses of the hydrolysis of anandamide by FAAH in T84 human colorectal carcinoma cells demonstrated a  $K_m$  of  $1.1 \pm 0.17 \mu\text{M}$ . (Fig. 4 B). This is close to the value that has been reported for human brain ( $2 \mu\text{M}$ , see Maccarrone *et al.* (Maccarrone *et al.* (1999) *Anal. Biochem.* 267:314-318)). Overall, the reported  $K_m$  values in the literature for FAAH reactions range widely, from  $0.8$  to  $80 \mu\text{M}$ , depending on the tissue, species and method used (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526). For instance, Desarnaud *et al.* (Desarnaud *et al.* (1995) *J. Biol. Chem.* 270, 6030-6035) found a  $K_m$  of  $12.7 \mu\text{M}$  using rat brain microsomes. In the N18 mouse neuroblastoma cell line, the  $K_m$  was determined to be  $9.0 \mu\text{M}$  (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86). Apart from species differences, the variability in these values has been ascribed to the observation that both the substrate and product of this enzyme can form micelles, which may affect the enzyme activity (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526).

[0070] *Validation of the FAAH assay using reference compounds:*

[0071] Several of the FAAH inhibitors that have been described in the literature were tested in the assay to validate its ability to identify inhibitors. Of the inhibitors that are commercially available, methyl arachidonyl fluorophosphate (MAFP), which is also an inhibitor of cytosolic phospholipase A<sub>2</sub>, is the most potent, with reported IC<sub>50</sub> values of  $1\text{-}3 \text{ nM}$  (Ueda *et al.* (2000) *Chem. Phys. Lipids* 108, 107-121; Deutsch *et al.* (1997) *Biochem. Pharmacol.* 53, 255-260). Its potency as an inhibitor of FAAH was confirmed with the determination of an IC<sub>50</sub> value of  $0.8 \text{ nM}$ .

[0072] Oleyl trifluoromethyl ketone, a transition-state inhibitor, has also been reported to be a potent inhibitor of FAAH, with an IC<sub>50</sub> of  $73.3 \text{ nM}$  in the studies here

presented, it was in the same range as the  $IC_{50}$  values of 28 - 41 nM found by Tiger *et al.* (2000; *Biochem. Pharmacol.* 59, 647-653).

[0073] Phenylmethanesulfonyl fluoride, an inhibitor of serine proteases, was shown to be an inhibitor of FAAH, although with a low potency. Its pIC<sub>50</sub> for the inhibition of rat brain FAAH in another group was between 5.92 and 4.16, depending on the pH (Holt *et al.* (2001) *Br. J. Pharmacol.* 133, 513-520). At a concentration of 100  $\mu$ M, it abolished anandamide hydrolysis in N18 mouse neuroblastoma cells (Maurelli *et al.* (1995) *FEBS Lett.* 377, 82-86). It was used at a concentration of 1.5 mM by Deutsch *et al.* (1993; *Biochem. Pharmacol.* 46, 791-796) to block FAAH activity in neuroblastoma and glial cells. At 25  $\mu$ M, it inhibited the hydrolysis of rat brain microsomal anandamide by 48 % (Desarnaud *et al.* (1995) *J. Biol. Chem.*, 270, 6030-6035). The  $IC_{50}$  value (16  $\mu$ M) obtained in this work thus corresponds well to the numbers reported in the literature.

[0074] Finally, product inhibition was tested by using the FAAH products oleic acid and arachidonic acid. Maurelli *et al.* (1995; *FEBS Lett.* 377, 82-86) found that 100  $\mu$ M anandamide abolished the activity of FAAH. In this work, these compounds inhibited FAAH activity with  $IC_{50}$  values in the low micromolar range (Table 1).

[0075] These results confirm that the assay provides a robust method for the evaluation of FAAH activity. The assay was successfully validated using reference inhibitors. As the assay may be performed simultaneously in multiple reactions, such as in a 96 well plate, for example, the assay is adaptable for high-throughput screening of compound collections as well as natural product or combinatorial libraries.

Table 1. Activity of known FAAH inhibitors in T84 membranes

COMPOUND	IC <sub>50</sub> (nM)	Literature (ref)
Methyl arachidonyl fluorophosphate	0.8 ± 0.7	2.5 <sup>(1)</sup> 1-3 <sup>(2)</sup>
Oleyl trifluoromethyl ketone	73.3 ± 19.8	39 <sup>(3)</sup> 24-41 <sup>(4)</sup>
Phenylmethylsulfonyl fluoride	15978 ± 8863	1200-69000 <sup>(5)</sup>
Arachidonic acid	931.4 ± 255.4	-
Oleic acid	1936 ± 401	-

The average ± S.E. of values obtained in 2-5 experiments, each done in triplicate, is given. The numbers in the column on the right refer to literature data. References : (1) : Deutsch *et al.* Biochem. Pharmacol. 1997, 53: 255-260. (2) : Ueda *et al.* Chem. Phys. Lipids 2000, 108 : 107-121. (3) Fowler *et al.* Br. J. Pharmacol. 2000, 131: 498-504. (4) Tiger *et al.* Biochem. Pharmacol. 2000, 59:647-653. (5) Holt *et al.* Br. J. Pharmacol. 2001, 133: 513-520.

The foregoing description, examples and accompanying figures generally describe the invention. The description is for purposes of providing illustrations; the present invention is not to be limited by the specific embodiments described herein. One of skill in the art will appreciate that various modifications of the invention may be made in addition to those described herein. Such modifications are intended to fall within the scope of the appended claims.

What is claimed is:

1. A method of assaying the activity of a fatty acid amide hydrolase comprising the steps of:

combining a sample suspected of containing a fatty acid amide hydrolase, with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;

contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;

separating the bound labeled complex from the incubated reaction mixture; and

determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.

2. The method of claim 1 wherein the sample comprises biological membranes, lipid bilayers, or micelles.

3. The method of claim 1 wherein the substrate is an endocannabinoid, a fatty acid ethanolamide or a fatty acid primary amide, or an analog of the foregoing.

4. The method of claim 1 wherein the substrate is anandamide.

5. The method of claim 1 wherein the substrate is oleamide.
6. The method of claim 1 wherein the substrate is 2-arachidonoylglycerol.
7. The method of claim 1 wherein the substrate is labeled with a radioisotope.
8. The method of claim 7 wherein the radioisotope is  $^3\text{H}$  or  $^{14}\text{C}$ .
9. The method of claim 1 wherein the substrate is labeled with a fluorescent label.
10. The method of claim 1 wherein the selective binding material comprises carbon.
11. The method of claim 8 wherein the selective binding material is activated charcoal.
12. The method of claim 9 wherein the activated charcoal comprises a filter.
13. The method of claim 1 wherein the selective binding material binds the labeled substrate but not the labeled product.
14. The method of claim 1 wherein the separating step comprises filtration, gravity settling or centrifugation.

15. The method of claim 1 wherein the determining step is performed via liquid scintillation counting or by measurement of fluorescence energy.
16. The method of claim 1 conducted in a multiwell plate.
17. The method of claim 1 comprising at least a portion of a high throughput screening program.
18. The method of claim 1 wherein the method is conducted in conjunction with a drug discovery effort.
19. A method of identifying a compound that modulates the activity of a fatty acid amide hydrolase comprising the steps of:  
comparing the activity of a fatty acid amide hydrolase as assayed by the method of claim 1, in the presence and in the absence of a test compound added to the reaction mixture;  
wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.
20. The method of claim 19 wherein the test compound is selected from a library of compounds.
21. The method of claim 19 wherein the test compound inhibits the activity of the fatty acid amide hydrolase activity.

22. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 5%.
23. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 20%.
24. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 50%.
25. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 80%.
26. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 95% or more.
27. The method of claim 21 wherein said test compound increases said fatty acid amide hydrolase activity.
28. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 5%.
29. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 30%.
30. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 50%.

31. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 70%.
32. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 100%.
33. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased between about two-fold to ten-fold.
34. The method of claim 19, which comprises the use of a multi-well plate.
35. The method of claim 19 conducted in a multiwell plate.
36. The method of claim 19 comprising at least a portion of a high throughput screening.
37. The method of claim 19 wherein the method is conducted in conjugation with a drug discovery effort.
38. The method of claim 1 wherein said fatty acid amide hydrolase is a mammalian fatty acid amide hydrolase.
39. The method of claim 1 wherein said fatty acid amide hydrolase is a porcine fatty acid amide hydrolase.

40. The method of claim 1 wherein said fatty acid amide hydrolase is a rodent fatty acid amide hydrolase.

41. The method of claim 1 wherein said fatty acid amide hydrolase is a murine fatty acid amide hydrolase.

42. The method of claim 1 wherein said fatty acid amide hydrolase is a rat fatty acid amide hydrolase.

43. The method of claim 1 wherein said fatty acid amide hydrolase is a mouse fatty acid amide hydrolase.

44. The method of claim 1 wherein said fatty acid amide hydrolase is a human fatty acid amide hydrolase.

45. A method for determining altered fatty acid amide hydrolase activity in a patient comprising:

obtaining a sample containing cells from the patient;

lysing the cells to form a cell lysate;

combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture;

incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;

contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the incubated reaction mixture; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with the activity of a to a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

46. The method of claim 45 wherein said patient is female.
47. The method of claim 46 wherein the female is pregnant or is seeking fertility treatment.
48. The method of claim 45 wherein the sample comprises blood, tissue or body fluid.
49. The method of claim 46 wherein the sample comprises lymphocytes.
50. The method of claim 45 wherein the cells are homogenized.
51. The method of claim 45 wherein the fatty acid amide hydrolase activity present in the cell lysate is partially or substantially purified from the sample.

52. The method of claim 45 wherein the predetermined determined value is from a control assay, a prior or subsequent sample from the patient, a sample from a normal individual, a sample from another patient, a standard FAAH, or a predetermined value.

## Pig FAAH Nucleic Acid Sequence (SEQ ID NO:1)

cggtcctcgg tgggagatca tggtcagga agaactgtgg gctgcgttct  
 ccggccctc cggggttgcc ctggcctgct gcttgggtgc agcggccttgc  
 gcccctgcgtt ggcccagtgc ccggatggcg cggggcgccggc cggcccgcc  
 gcgacagagg cagaagcgg ccctggagac catggacaag gcggcgcagc  
 gcttcggctt ccagaacccc gatctggact cggagatgct gctggccctg  
 ccaactgcgtt cccatgcgtt agctggtaca gaaggtaaca agtggggagc tggccatc  
 ggctgtgtc ttttccttacc tgcaaaaaggc ctgggaagtgc aacagaggga  
 ccaactgcgtt gaccacctac ctggcagact gtgaggctca gctgtgccag  
 gcgcccgccggc agggcctgct ctacgggtgc cccgtcagcc tcaaggagtg  
 cttcagctgc aaggccatg actccacgtt gggcttggc cggaaaccagg  
 gacaccaggc agaatgtgac tgcgtgggg tgcagggtct gaaactgcag  
 ggtgctgtgc ctttcgtgca caccaacgtc ccccgatcca tggccatc  
 tgactgcgtt aacccttctt ttggccagac cacgaaccca tggatgtcgt  
 ccaagagccc gggcggtcc tcggggaggtg agggggccctt cattgtct  
 ggaggctccc cactgggtt aggcaccggc atcgggggca gatccgcctt  
 tccctccggcc ttctgtggca tctggggcat caaaccacg gggaaaccgca  
 tcagcaagag tggctgtgaag ggctctgtct atggacaggat agcagtgcag  
 ctctcagtttgg gccccatggc gcggggacgtt gggggccctt cattgtgc  
 gcgtgcgtt ctgtgcgtt acatgttccg cctggacccccc acgggtgc  
 ccctggccctt caacggggat gtctacgca gctctcggcc cctgtcgtt  
 gggtattatg agaccgacaa ctacaccatg cccacggcc ccatgaggcg  
 ggcctctgtt gagaccaaggc ggaggcttga ggctggggcc cccacggcc  
 ttcccttccctt gcccggccaaat accccacg ctttggggcc cctgtcaac  
 ggcgggctt tcaatgtatgg tggggagagg ttgctacaga acttcgaagg  
 cgattacgtt gactcctgtt taggggaccc tggcttccat ctgaggctgc  
 ccaaattgtt taaaggactt ctggctttca tgctgaggcc tctgctccca  
 aggttggcag gctttcttca cagctgggg cctcggttccat ctggaaagct  
 ctggggactt cagcacggata ttggatgtt cctgtactcc gtttggggcc  
 agtggcgagc gctggacccgtt gatgtgggtgc taacccttcat gctgagcc  
 gccccttagact tgaatggccccc aggcaaggcc acaggggccg tcaatgtt  
 gctgctcttca aactgccttgc acttcccccgc ggggggtggc cctgtcacca  
 cggtgacttc cggggacggag gcccagatgg agcattacaa gggctacttt  
 gggggacatgg gggacaagggt ggtgcagaag gcatgttca gggggcc  
 gctgcctgtt gcccgttca gtttgggttcat gggggcc gggggcc  
 gtttgggttcat gggggcc gtttgggttcat gggggcc gggggcc  
 cccttcgttca cggggccccc agggggcc gggggcc  
 tcccgccca gcccggccat gacacaactt ccaccgttca agaaaatgtt  
 caacccatgg cagaggcttcc cccatgttca cccctccccc ctggccagaag  
 cccagaaatcc ctgaggcttgc accttgc tccctgggttcc cctgtcttgc  
 cctgaccccg ccaatgtggc agcttgc ttttgc ttttgc  
 ccaaccgttca aaaaaccgggtt cctgttca atacttttgc gtttgggtt  
 tttagggcgtt ggggggttggc gacccgttca ttttgc ttttgc  
 atgtccgttca ctttgc ttttgc aagccgttca ggttccgttca acttgc  
 agacaccggc ttctccgttca gggccgttca gcccaggact ttttgc  
 gccccccggcc taagcccttac ttttgc ttttgc attgttcc ttttgc  
 ctgttca gggggcc ttttgc ttttgc

## Pig FAAH Amino Acid Sequence (SEQ ID NO:2)

MVQEELWAAF SGPSGVALAC CLVAAALALR WSSRRMARGA AARARQRQQA  
 ALETMDKAAQ RFRLQNPDL D SEMLLALPLP QLVQKVRSGE LSPEAVLFSY  
 LQKAWEVNRG TNCVTTYLAD CEAQLCQAPG QGLLYGVPVS LKECFSCKGH  
 DSTLGLSRNQ GTPAECDCVV VQVILKLOGAV PFVHTNVPQS MFSYDCSNPL  
 FGQTTNPWMS SKSPGGSSGG EGALIAAGGS PLGLGTDIGG SIRFPSAFCG  
 ICGIKPTGNR ISKSGLKGSV YGQVAVQLSV GPMARDVESL ALCLRALLCE  
 DMFRLDPTVP PLPFNEEVYA SSRPLRVGYY ETDNYTMPTP AMRRALLETK  
 RSLEAAAGHTL IPFLPANIPH ALEALSTGGL FSDGGKRLLQ NFEGDYVDSC  
 LGDLISILRL PKWLKGLLAF MLRPLLPRLA GFLSSLRPRS AGKLWELQHE  
 IEMYRHNSVIA QWRALDLDVV LTPMLSPALD LNAPGKATGA VSYTLLYNCL  
 DFPAGVVPVPT TVTAEDEAQM EHYKGYFGDI WDKVVQKAMK RSVGLPVAVQ  
 CVALPWQEEL CLRHMREVER LMAPGRQPS

## Mouse FAAH Nucleic Acid Sequence (SEQ ID NO:3)

atgggtgctga gccaagggtgt gaccgcgctg tctggactct ccggggtttg  
 cctagcctgc agcttgctgt cggccggcggt ggtcctgcga tggaccagga  
 gccagacccgc ccggggcgcg gtgaccaggg cgccggcagaa gcagcgagcc  
 ggcctggaga ccatggacaa ggcgtgtcag cgcttccgc tgcagaatcc  
 tgacctggat tcagaggcct tgctggctct gcccctgctc caactggtag  
 agaagttaca gagtggggaa ctgtccccag aagctgtct cttaacccat  
 ctgggaaagg cctggaaagt gaacaaaggg accaactgtg tgacctccta  
 tctgactgac tggagactc agctgtccca ggcggccatcc gtttccatcc  
 tctatggcgt ccccggtgagc ctcaaggaat gtttccatcc caaggggccat  
 gtttccacac tgggcttaag tttgaacgg ggtgtgacat cggagagtg  
 ctgtgtggtg gtgcaggta tgaagctgca gggagctgtg ccctttgtgc  
 acaccaacgt ccccccgtcc atgctaagct atgactgcag taacccctc  
 tttggccaga ccatgaaccc gtggaaagccc tccaaagatc caggaggatc  
 ctcaggggtt gagggggctc tcattggat tggaggctcc cctctgggtt  
 taggcactga catcgccggc agcatccgt tcccttctgc ttctctgtggc  
 atctgtggcc tcaaggctac tgggaaccgc ctcagcaaga gtggcctgaa  
 gagctgtgtt tatggacaga cagcagtgc gtttctgtt ggcggccatgg  
 cacgggatgt ggatagcctg gcattgtgca taaaaggccct actttgtgag  
 gatttgttcc gtttggactc caccatcccc cccttgcct tcagggagga  
 gatctacaga agttctcgac cccttcgtt gggatactat gaaactgaca  
 actacaccat gcccactcca gccatgagga gggctgtat gggagaccaag  
 cagagtctcg aggtgtctgg ccacacgctg gtcccttctt taccaccaaa  
 cataccttat gcccggagg tcctgtcggc aggtggctg ttcagtgtatg  
 gtggctgctc ttttctccaa aacttcaaag ggcactttgt ggatccctgc  
 ttgggggacc tggctttagt gctgaagctg cccagggtgt taaaaaaact  
 gctgagcttc ctgctgaagc ctctgtttcc tcggctggca gcctttctca  
 acagtatgtg tcctcggtca gcccggggact tggggaaact gcagcatgag  
 attgagatgt atcgccagtc cgtcattgcc cagtggaaagg caatgaaatt  
 ggacgtggtg ctaaccccca tgctgggtcc tgctctggat ttgaacacac  
 cggggcagagc cacaggggtt atcagctaca ctgttctcta taactgcctg  
 gacttccctg cgggggtgtt gcctgtcacc actgtgaccg ctgaggacga  
 tgcccagatg gaacactaca aaggctactt tggggatatg tggggacaaca  
 ttctgaagaa gggcatgaaa aagggtatag gcctgcctgt ggctgtcag  
 tgcgtggctc tgccctggca ggaagagctg tgcgtggctt tcatgcggga

ggtggAACGG ctgatgacCC ctgaaaAGCG gccatcttga

Mouse FAAH Amino Acid Sequence (SEQ ID NO:4)

MVLSEVWTAL SGLSGVCLAC SLLSAAVVLR WTRSQTARGA VTRARQKQRA  
 GLETMDKAVQ RFRLQNPDLQ SEALLALPLL QLVQKLQSGE LSPEAVLFTY  
 LGKAWEVNKG TNCVTSYLTQ CETQLSQAPR QGLLYGVPVS LKECFSYKGH  
 ASTLGLSLNE GVTSESDCVV VQVLKLQGAV PFWHTNVPQS MLSYDCSNPL  
 FGQTMNPWKP SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG  
 ICGLKPTGNR LSKSGLKSCV YGQTAVQLSV GPMARDVDSL ALCMKALLCE  
 DLFRLDSTIP PLPFREEIYR SSRPLRVGYY ETDNYTMPTP AMRRAVMETK  
 QSLEAAAGHTL VPFLPNNIYP ALEVLSAGGL FSDGGCSFLQ NFKGDFVDP  
 LGDLVLVLLKL PRWFKKLLSF LLKPLFPRLA AFLNSMCPRS AEKLWELQHE  
 IEMYRQSVIA QWKAMNLDVV LTPMLGPALD LNTPGRATGA ISYTVLYNCL  
 DFPAGVVPVT TVTAEDDAQM EHYKGYFGDM WDNILKKGMK KGIGLPVAVQ  
 CVALPWQEEL CLRPMREVER LMTPEKRPS

Rat FAAH Nucleic Acid Sequence (SEQ ID NO:5)

ggtttgtgcg agccgagttc tctcggtgg cggtcggctg caggagatca  
 tggtgctgag cgaagtgtgg accacgctgt ctggggctc cggggtttgc  
 cttagcctgca gcttgttgc ggcggcggc gtccctgcgt ggaccggcg  
 ccagaaggcc cggggcgcgg cgaccaggc gcggcagaag cagcgagcca  
 gcctggagac catggacaag gcggtgcagc gttccggct gcagaatcct  
 gacctggact cggaggcctt gctgaccctg cccctactcc aactggtaca  
 gaagttacag agtggagagc tgcctccaga ggctgttgc tttacttacc  
 tgggaaaggc ctgggaaagtg aacaaaggga ccaactgcgt gaccccttat  
 ctgaccgact gtgagactca gctgtcccgag gccccacggc agggcctgct  
 ctatgggtgc cctgtgagcc tcaaggaatg cttcagctac aagggccacg  
 actccacact gggcttgagc ctgaatgagg gcatgtgc tttacttacc  
 tgggtggc tgcaagtgtt gaagctgcac ggactgtgc cctttgtgca  
 taccaatgtc ccccaagtcca tggtaagctt tgactgcgt aaccctct  
 ttggccagac catgaaccca tggaaagtctt ccaagagccc aggaggttcc  
 tcagggggctt agggggctt cattggatct ggaggttccc ctctggggtt  
 aggcaactgac attggccggca gcattccgggtt cccttctgcc ttctgcggca  
 tctgtggcctt caagcctact ggcaaccggc tcagcaagag tggcctgaag  
 ggctgtgtct atggacagac ggcagtgcag ctttcttgc gccccatggc  
 ccgggatgtg gagagcctgg cgctatgcct gaaagctcta ctgtgtgagc  
 acttggttcac tttggaccctt accgtgcctc ctttgcctt cagagaggag  
 gtctatagaa gttctagacc cctgcgtgtg ggtactatg agactgacaa  
 ctataccatg cccagcccaag ctatgaggag ggctctgata gagaccaagc  
 agagacttga ggctgtggc cacacgctga ttcccttctt acccaacaac  
 ataccctacg ccctggaggt cctgtctgcg ggcggcctgt tcagtgacgg  
 tggccgcagt tttctccaaa acttcaaagg tgactttgtg gatccctgct  
 tgggagacct gatcttaatt ctgaggctgc ccagctgggtt taaaagactg  
 ctgagccctt tgctgaagcc tctgtttcct cggctggcag ctttctcaa  
 cagtatgcgt cctcggtcag ctgaaaagct gttggaaactg cagcatgaga  
 ttgagatgtt tcgcccgtt gtgattgccc agtggaaagc gatgaacttg  
 gatgtgtgc tgaccccccattt gttggccctt gctctggatt tgaacacacc  
 gggcagagcc acaggggcta tcagctacac cggtctctac aactgcctgg  
 acttccctgc ggggtgggtt cctgtcacca ctgtgaccgc cgaggacat

gcccagatgg aactctacaa aggctacttt gggatatatct gggacatcat  
 cctgaagaag gccatgaaaa atagtgtcgg tctgcctgtg gctgtgcagt  
 gcgtggctc gccctggcag gaagagctgt gtctgaggtt catgcggag  
 gtggAACAGC ttagtgcaccc tcaaaaagcag ccatcgtgag ggtcggtcat  
 cccgcagctc tggaggacct aaggcccatt cgctgtcac ttagccccca  
 tgtattcagg agccaccacc cacgaggaa cgcccagcac agggaaagagg  
 tgtctacctg ccctccctg gactcctgca gccacaacca agtctggacc  
 ttccctccccg ttatggtcta cttccatcc tgattccctg ctttttatgg  
 cagccagcag gaatgacgtg gccaaggat cacaacatt caaaaacaat  
 gcgttatact attttctggg tatctccatt agggccctgg gaaccagagt  
 gctgggaagg ctgtccagac cctccagagc tggctgtaac cacatcactc  
 tcctgctcca aagcctccct agttctgtca cccacaagat agacacaggg  
 acatgtcctt ggcacttgac tcctgtcctt ccttccttat tcagattgac  
 cccagcctt g atggaccctg cccctgcact tccttcctca gtccacactc  
 ctgcccacac gcccctttt tggctcctct atttggtgtg gagacaaggt  
 ttctctcagt agccctggct gtccaggacc tcactctgt a gatgaggctg  
 gcttcact cacaaggctg cctgcctggg tgctggatt aaaggcgtat  
 gccaccacaa agaaaaaaaaa aa

## Rat FAAH Amino Acid Sequence (SEQ ID NO:6)

MVLSEVWTTL SGVSGVCLAC SLLSAAVVLR WTGRQKARGA ATRARQKQRA  
 SLETMDKAVQ RFRLQNPDLQ SEALLTLPLL QLVQKLQSGE LSPEAVFFTY  
 LGKAWEVNKG TNCVTSYLTQ CETQLSQAPR QGLLYGVPVS LKECFSYKGH  
 DSTLGLSLNE GMPSESDCVV VQVLKLQGAV PFVHTNVPQS MLSFDCSNPL  
 FGQTMNPKWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG  
 ICGLKPTGNR LSKSGLKGCV YGQTAQVQLSI GPMARDVESL ALCLKALLCE  
 HLFTLDPTVP PLPFREEVYR SSRPLRVGYY ETDNYTMAPSP AMRRALIETK  
 QRLEAAAGHTL IPFLPNNIPY ALEVLSAGGL FSDGGRSFLQ NFKGDFVDPC  
 LGDLILILRL PSWFKRLLSL LLKPLFPRLA AFLNSMRPRS AEKLWKLQHE  
 IEMYRQSVIA QWKAMNLDVL LTPMLGPALD LNTPGRATGA ISYTVLYNCL  
 DFPAGVVVPVT TVTAEDDAQM ELYKGYFGDI WDIILKKAMK NSVGLPVAVQ  
 CVALPWQEEQ CLRFMREVEQ LMTPQKQPS

## Human FAAH Nucleic Acid Sequence (SEQ ID NO:7)

tgccggggcg taggcagcag caggctgaag ggatcatggt gcagttacgag  
 ctgtggggcg cgctgcctgg cgccctccggg gtcgcctgg cctgctgtt  
 cgtggcgccg gccgtggccc tgcgtggc cggcgccgg acggcgccgg  
 ggcgtgggtt cggggcgca cagaagcagc gagcggccct ggagaacatg  
 gacagggcgg cgccagcgctt ccggctccag aacccagacc tggactcaga  
 ggcgtgtcta gccctgcccc tgcctcagct ggtgcagaag ttacacagta  
 gagagctggc ccctgaggccc gtgtcttca cctatgtggg aaaggccctgg  
 gaaagtgaaca aagggaccaa ctgtgtgacc tcctatctgg ctgactgtga  
 gactcagctg ttcaggccc caaggcaggg cctgctctat ggcgtccctg  
 tgagcctcaa ggagtgcctt acctacaagg gccaggactc cacgtggc  
 ttgagcctga atgaaggggt gcccggag tgcgacagcg tagtggtgca  
 tggctgtaa ctgcagggtg ccgtccctt cgtgcacacc aatgttccac  
 agtccatgtt cagctatgac tgcagtaacc ccctcttgg ccagaccgtg  
 aacccatgga agtccctcaa aagcccagg ggctctcag ggggtgaagg  
 gcccctcatc gggctggag gctccccctt gggcttaggc actgatatcg

gaggcagcat ccgcttcccc tcctccttct gcggcatctg cggcctcaag  
 cccacaggg aaccgcctcg caagagtggc ctgaagggct gtgtctatgg  
 acaggaggca gtgcgtctct ccgtggcccg catggcccg gacgtggaga  
 gcctggcact gtgcctgcga gccctgctgt gcgaggacat gttccgcttgc  
 gaccccaactg tgccctccctt gcccttcaga gaagaggtct acaccagctc  
 tcagcccctg cgtgtgggt actatgagac tgacaactat accatgcct  
 ccccgccat gaggcgccc gtgcggaga ccaaacagag ctttggagct  
 gcggggcaca cgctggttcc cttttgcca agcaacatac cccatgcct  
 ggagacccctg tcaacaggtg ggctttcag tggatggc cacaccccttcc  
 tacagaactt caaagggtat ttgcgtggacc cctgcctggg ggacctggc  
 tcaattctga agcttccca atggcttaaa ggactgctgg ctttccctgg  
 gaaggcctctg ctgccaaggc tgcagcttt cctcagcaac atgaagtctc  
 gttcggctgg aaaactctgg gaactgcagc acgagatcga ggtgtaccgc  
 aaaaccgtga ttgcggcgtg gaggcgctg gacctggatg tgggtctgac  
 ccccatgcgtg gccctgcctc tggacttggaa tgcccccaggc agggccacag  
 gggccgtcag ctacactatg ctgtacaact gcctggactt ccctgcaggg  
 gtggtgctgt tcaccacggt gactgctgag gacgaggccc agatggaaaca  
 ttacaggggc tactttgggg atatctggga caagatgctg cagaaggc  
 tgaagaagag tggggggctg ccggggcccg tgcagtgtgt ggctctgccc  
 tggcaagaag agttgtgtct gcggttcatg cgggagggtgg agcgactgat  
 gaccctgtaa aagcagtcat cctgatggct ctggctccag aggacctgag  
 actcacactc tctgcagccc agcctagtca gggcacagct gcccctgctgc  
 cacagcaagg aaatgtccctg catggggcag aggctccgt gtcctctccc  
 ccaaccctt gcaagaagcgc ccgactccct gagtctggac ctccatccct  
 gctctggtcc cctcttcttgc tcctgatccc tccaccccca tgtggcagcc  
 catgggtatg acataggcca aggcccaact aacagtcaag aaacaaaaaa  
 aaaaaaaaaaaa aaa

Human FAAH Amino Acid Sequence (SEQ ID NO:8)

MVQYELWAAL PGASGVALAC CFVAAAVALR WSGRRRTARGA VVRARQKQRA  
 GLENMDRAAQ RFLQLNPDLI SEALLALPLP QLVQKLHSRE LAPEAVLFTY  
 VGKAWEVNKG TNCVTSYLAQ CETQLSQAPR QGLLYGVPVS LKECFTYKGQ  
 DSTLGLSLNE GVPACEDSVV VHVLKLQGAV PFVHTNVPQS MFSYDCSNPL  
 FGQTVNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSSFCG  
 ICGLKPTGNR LSKSGLKGCV YGQEAVRLSV GPMARDVESL ALCLRALLCE  
 DMFRLDPTVP PLPFREEVYT SSQPLRVGYY ETDNYTMAPSP AMRRAVLETK  
 QSLEAAGHTL VPFLPSNIPH ALETLSTGGL FSDGGHTFLQ NFKGDFVDPC  
 LGDLVSLKLPQWLKGLLAF LVKPLLPLRS AFLSNMKSRS AGKLWELQHE  
 IEVYRKTVIA QWRALDLDVV LTPMLAPALD LNAPGRATGA VSYTMLYNCL  
 DFPAGVVPVT TVTAEDEAQM EHYRGYFGDI WDKMLQKGMK KSVGLPVAVQ  
 CVALPWQEEL CLRPMREVER LMTPEKQSS

**ABSTRACT**

The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering, addictions.

1/4

Step 1 : incubate  $^3$ H-anandamide  
with FAAH-containing membranes




Figure 1

2/4





Figure 2.

60420065 102102

3/4



**Figure 3**

4/4




Figure 4A

A




Figure 4B

## SEQUENCE LISTING

<110> Barbier, Ann Johanna  
 Wilson, Sandy J.  
 Mazur, Curt

<120> Assay for Determining the Activity of Fatty Acid Amide Hydrolase

<130> PRI0002

<160> 8

<170> PatentIn version 3.1

<210> 1  
 <211> 2300  
 <212> DNA  
 <213> Sus scrofa

<400> 1						
cggtcctcgg	tgggagatca	tggtgcagga	agaactgtgg	gctgcgttct	ccggccccctc	60
cgggggttggc	ctggcctgct	gcttggtgcc	agcggcccttgc	gccctgcgtt	ggtccagtcg	120
ccggatggcg	cggggcgcgg	cggccgggc	gacacagagg	cagcaagcgg	ccctggagac	180
catggacaag	cgccgcgcgc	gttccggct	ccagaacccc	gatctggact	cgagatgct	240
gtctggccctg	ccactgcctc	agctggtaca	gaaggtacga	agtggggagc	tgtctccaga	300
ggctgtgctc	ttttcctacc	tgcaaaaggc	ctggaaagtg	aacagagggg	ccaactgcgt	360
gaccacctac	ctggcagact	gtgaggctca	gctgtgccag	gccccgggc	aggcctgct	420
ctacggtgtc	cccgtcagcc	tcaaggagtg	cttcagctgc	aaggccatg	actccacgct	480
gggcttgagc	cggaaccagg	ggacaccaggc	agaatgtgac	tgcgtggtg	tgcaggtgct	540
gaaactgcag	ggtgctgtgc	ctttcgtgca	caccaacgtc	ccccagtcca	tgttcagcta	600
tgactgcagt	aaccccccct	ttggccagac	cacgaaccca	tggatgtcgt	ccaagagccc	660
gggcggctcc	tcgggaggtg	agggggccct	cattgctgct	ggaggctccc	cactggcctt	720
aggcaccgac	atcgaaaaa	gcattccgctt	tccctccgcc	ttctgtggca	tctgcggcat	780
caaaccacg	gggaaccgca	tcagcaagag	tggtctgaag	ggctctgtct	atggacaggt	840
agcagtgcag	ctctcagtgg	gccccatggc	gccccatggc	gagagcctgg	ccctgtgcct	900
gcgtgcgtc	ctgtgcgaag	acatgttccg	cctggacccc	acgggtgcctc	ccctgcctt	960
caacgaggag	gtctacgcaa	gctctcgcc	cctgcgtgtc	gggtattatg	agaccgacaa	1020
ctacaccatg	cccacgcgg	ccatgaggcg	ggccctgctg	gagaccaagc	ggagccttga	1080
ggctgcgggc	cacacgctga	ttcccttcct	gccggccaac	atacccacg	ctctggaggc	1140
cctgtcaacg	ggcgggcctc	tcagtgtgg	tggaaagagg	ttgctacaga	acttcgaagg	1200
cgattacgtg	gactcctgct	tagggacct	gatctcaatt	ctgaggctgc	ccaaatggct	1260
taaaggactg	ctggcttca	tgctgaggcc	tctgtccca	aggtggcag	gctttctcag	1320
cagcctgagg	cctcggcgg	ctggaaagct	ctggaaactg	cagcacgaga	ttgagatgta	1380
ccgtcactcc	gtgattgccc	agtggcgagc	gctggacctg	gatgtggtgc	taaccccat	1440
gctgagccct	gccctagact	tgaatgcccc	aggcaaggcc	acagggcccg	tcaactacac	1500
gctgctctac	aactgcctgg	acttccccgc	gggggtggtg	cctgtcacca	cggtgactgc	1560

cgaggacgag gcccagatgg agcattacaa gggctacttt gggacattt gggacaagg 1620  
 ggtgcagaag gccatgaaga ggagcgtgg gctgcctgtg gccgtcaggt gtgtggctct 1680  
 gcccctggcag gaggagctgt gttgcgggtt catgcgggag gtggagcgcac tgatggctcc 1740  
 tggcggcag ccctcctgac cgctgccccc ccggcccccc aggacctgag acccaactgga 1800  
 tccgcgccca gcggagtcag gacacaactg ccaccgtgca agaaaatgtt caacctcagg 1860  
 cagaggcttc ccggctcttc cccctcgccc ctgcccagaag cccagaacca ctgagtctgg 1920  
 accttgcctct tcccgtggtc cctgcctctgc cctgaccccg ccaatgtggc agctagtggg 1980  
 tatgacatgg caaaggcccc ccaaccgtca aaaaccgggtt cctggctctcc atactttctg 2040  
 gcagtcgttg ttagggcagt gggggttggg gacctgacct tctggaaaccc gactccagcc 2100  
 atgtccgtct cgtgctgcag aagcttctct ggctctcgtc actcacgggc agacaccggc 2160  
 ttctccgagt gggccttgca gcccaggact tcaccccgcc gccccagcc taagccctac 2220  
 tttgcgaggg attgtcttct ctccctggcct ctgctgaggg tgccctttct gctccctctac 2280  
 cattaaatcc tttgaggccc 2300

<210> 2  
 <211> 579  
 <212> PRT  
 <213> Sus scrofa

<400> 2

Met Val Gln Glu Glu Leu Trp Ala Ala Phe Ser Gly Pro Ser Gly Val  
 1 5 10 15

Ala Leu Ala Cys Cys Leu Val Ala Ala Ala Leu Ala Leu Arg Trp Ser  
 20 25 30

Ser Arg Arg Met Ala Arg Gly Ala Ala Ala Arg Ala Arg Gln Arg Gln  
 35 40 45

Gln Ala Ala Leu Glu Thr Met Asp Lys Ala Ala Gln Arg Phe Arg Leu  
 50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Met Leu Leu Ala Leu Pro Leu Pro  
 65 70 75 80

Gln Leu Val Gln Lys Val Arg Ser Gly Glu Leu Ser Pro Glu Ala Val  
 85 90 95

Leu Phe Ser Tyr Leu Gln Lys Ala Trp Glu Val Asn Arg Gly Thr Asn  
 100 105 110

Cys Val Thr Thr Tyr Leu Ala Asp Cys Glu Ala Gln Leu Cys Gln Ala  
 115 120 125

Pro Gly Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
 130 135 140

145 Ser Cys Lys Gly His Asp Ser Thr Leu Gly Leu Ser Arg Asn Gln  
 150 155 160

Gly Thr Pro Ala Glu Cys Asp Cys Val Val Val Gln Val Leu Lys Leu  
 165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe  
 180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Thr Asn Pro Trp  
 195 200 205

Met Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
 210 215 220

Ile Ala Ala Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
 225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Ile Lys Pro  
 245 250 255

Thr Gly Asn Arg Ile Ser Lys Ser Gly Leu Lys Gly Ser Val Tyr Gly  
 260 265 270

Gln Val Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu  
 275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg  
 290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Asn Glu Glu Val Tyr Ala  
 305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
 325 330 335

Met Pro Thr Pro Ala Met Arg Arg Ala Leu Leu Glu Thr Lys Arg Ser  
 340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Ala Asn Ile  
 355 360 365

Pro His Ala Leu Glu Ala Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly  
 370 375 380

Gly Lys Arg Leu Leu Gln Asn Phe Glu Gly Asp Tyr Val Asp Ser Cys  
 385 390 395 400

Leu Gly Asp Leu Ile Ser Ile Leu Arg Leu Pro Lys Trp Leu Lys Gly  
 405 410 415

Leu Leu Ala Phe Met Leu Arg Pro Leu Leu Pro Arg Leu Ala Gly Phe  
 420 425 430

Leu Ser Ser Leu Arg Pro Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln  
 435 440 445

His Glu Ile Glu Met Tyr Arg His Ser Val Ile Ala Gln Trp Arg Ala  
 450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ser Pro Ala Leu Asp  
 465 470 475 480

Leu Asn Ala Pro Gly Lys Ala Thr Gly Ala Val Ser Tyr Thr Leu Leu  
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
 500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly  
 515 520 525

Asp Ile Trp Asp Lys Val Val Gln Lys Ala Met Lys Arg Ser Val Gly  
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Ala Pro Gly Arg  
 565 570 575

Gln Pro Ser

<210> 3  
 <211> 1740  
 <212> DNA  
 <213> Mouse

<400> 3	
atggtgctga gcgaagtgtg gaccgcgtg tctggactct ccggggtttgcctagcctgc	60
agcttgcgtt cggccggcggt ggtcctgcga tggaccagga gccagaccgc ccggggcgcg	120
gtgaccaggg cgcggcagaa gcagcgagcc gcctggaga ccatggacaa ggccgtgcag	180
cgcttccggc tgcagaatcc tgacctggat tcagaggcct tgctggctct gcccctgctc	240
caactggta cagaagttaca gagtggggaa ctgtccccag aagctgtgt cttaacctac	300
ctggaaagg cctggaaatgtaa gacaaaagg accaactgtg tgacacctcta tctgactgac	360
tgtgagactc agctgtccca ggcacccacgg cagggcctgc tctatggcgt ccccggtgagc	420
ctcaagaaat gcttcagcta caagggccat gcttccacac tgggcttaag tttgaacgag	480
ggtgtgacat cggagagtgta ctgtgtggtg gtgcaggatc tgaagctgca gggagctgtg	540
ccctttgtgc acaccaacgt cccccagtc atgctaagct atgactgcag taacccctc	600
tttggccaga ccatgaaccc gtggaaagccc tccaagagtc caggaggatc ctcagggggt	660
gagggggctc tcattggatc tggaggctcc cctctgggtt taggcactga catggcgcc	720

atccggc tcccttctgc cttctgtggc atctgtggcc tcaagcctac tgggaaccgc 780  
 ctcagcaaga gtggcctgaa gagctgtgtt tatggacaga cagcagtgc gctttctgtt 840  
 ggccccatgg cacgggatgt ggatagcctg gcattgtgc taaaaggccct actttgtgag 900  
 gatttgttcc gcttggactc caccatcccc cccttgcct tcagggagga gatctacaga 960  
 agttctcgac cccttcgtgt gggatactat gaaactgaca actacaccat gcccactcca 1020  
 gccatgagga gggctgtgat ggagaccaag cagagtctcg aggctgtgg ccacacgctg 1080  
 gtcccccttct taccaaacaa cataccttat gcccctggagg tcctgtcgcc aggtgggctg 1140  
 ttcaagtatg gtggctgctc ttttctccaa aacttcaaag gcgactttgt ggatccctgc 1200  
 ttgggggacc tggcttttagt gctgaagctg cccaggtgg taaaaaaaact gctgagcttc 1260  
 ctgctgaagc ctctgttcc tggctggca gccttctca acagttatgt tcctcggtca 1320  
 gcccggaaagc tgtgggaaact gcagcatgag attgagatgt atcgccagtc cgtcattgcc 1380  
 cagtggaaagg caatgaactt ggacgtggtg ctaaccccca tgctgggtcc tgctctggat 1440  
 ttgaacacac cgggcagagc cacagggct atcagctaca ctgttctcta taactgcctg 1500  
 gacttccctg cgggggtggt gcctgtcacc actgtgaccc ctgaggacga tgcccagatg 1560  
 gaacactaca aaggctactt tgggatatg tgggacaaca ttctgaagaa gggcatgaaa 1620  
 aagggtatag gcctgcctgt ggctgtgcag tgctggctc tgccctggca ggaagagctg 1680  
 tgtctgcgggt tcatgcggga ggtggAACGG ctgatgaccc ctgaaaagcg gccatcttga 1740

<210> 4  
 <211> 579  
 <212> PRT  
 <213> Mouse  
 <400> 4

Met Val Leu Ser Glu Val Trp Thr Ala Leu Ser Gly Leu Ser Gly Val  
 1 5 10 15

Cys Leu Ala Cys Ser Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr  
 20 25 30

Arg Ser Gln Thr Ala Arg Gly Ala Val Thr Arg Ala Arg Gln Lys Gln  
 35 40 45

Arg Ala Gly Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu  
 50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Leu  
 65 70 75 80

Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val  
 85 90 95

Leu Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
 100 105 110

Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala

115

120

125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
 130 135 140

Phe Ser Tyr Lys Gly His Ala Ser Thr Leu Gly Leu Ser Leu Asn Glu  
 145 150 155 160

Gly Val Thr Ser Glu Ser Asp Cys Val Val Gln Val Leu Lys Leu  
 165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu  
 180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp  
 195 200 205

Lys Pro Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
 210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
 225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro  
 245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Ser Cys Val Tyr Gly  
 260 265 270

Gln Thr Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Asp  
 275 280 285

Ser Leu Ala Leu Cys Met Lys Ala Leu Leu Cys Glu Asp Leu Phe Arg  
 290 295 300

Leu Asp Ser Thr Ile Pro Pro Leu Pro Phe Arg Glu Glu Ile Tyr Arg  
 305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
 325 330 335

Met Pro Thr Pro Ala Met Arg Arg Ala Val Met Glu Thr Lys Gln Ser  
 340 345 350

Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Asn Asn Ile  
 355 360 365

Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly  
 370 375 380

Gly Cys Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
 385 390 395 400

Gly Asp Leu Val Leu Val Leu Lys Leu Pro Arg Trp Phe Lys Lys  
 405 410 415

Leu Leu Ser Phe Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe  
 420 425 430

Leu Asn Ser Met Cys Pro Arg Ser Ala Glu Lys Leu Trp Glu Leu Gln  
 435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala  
 450 455 460

Met Asn Leu Asp Val Val Leu Thr Pro Met Leu Gly Pro Ala Leu Asp  
 465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu  
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
 500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly  
 515 520 525

Asp Met Trp Asp Asn Ile Leu Lys Lys Gly Met Lys Lys Gly Ile Gly  
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys  
 565 570 575

Arg Pro Ser

<210> 5  
 <211> 2472  
 <212> DNA  
 <213> *rattus rattus*

<400> 5  
 ggtttgcgcg agccgagttc tctcggttgg cggtcggctg caggagatca tggtgctgag 60  
 cgaagtgtgg accacgctgt ctggggtctc cggggtttgc ctggcctgca gcttgggtgc 120  
 ggcggcggtg gtcctgcgat ggaccggcg ccagaaggcc cggggcgcgg cgaccaggc 180  
 gcggcagaag cagcggagcca gcctggagac catggacaag gcggtgcagc gcttccggct 240  
 gcagaatcct gacctggact cggaggccct gctgaccctg cccctactcc aactggtaca 300  
 gaagttacag agtggagagc tgtccccaga ggctgtgttc tttacttacc tggaaaggc 360  
 ctggaaagtg aacaaaggga ccaactgcgt gaccccttat ctgaccgact gtgagactca 420  
 gctgtcccaag gccccacggc agggcctgct ctatggtgct cctgtgagcc tcaaggaatg 480  
 cttcagctac aagggccacg actccacact gggcttgagc ctgaatgagg gcatgccatc 540

ggaatctgac	tgtgtgggg	tgcaagtgtt	gaagctgcag	ggagctgtgc	cctttgtgca	600								
taccaatgtc	ccccagtc	tgttaagctt	tgactgcagt	aaccctctct	ttggccagac	660								
catgaaccca	tggaagtcc	ccaa	gagccc	aggaggttcc	tcagggggtg	agggggctct	720							
cattggatct	ggaggttccc	ctctggg	ttt	aggcaactgac	attggcggca	gcatccggtt	780							
cccttctgcc	ttctgcggca	tctgtggc	ctt	caagcctact	ggcaaccg	cc tcagcaagag	840							
tggcctgaag	ggctgtgtct	atggacagac	ggcagtgcag	ctttctt	gccccatggc	900								
ccgggatgtg	gagagcctgg	cgctatgc	ctt	gaaagctcta	ctgtgtg	gac acttgttac	960							
cttggaccct	accgtgc	ccttgc	cc	cagagaggag	gtctatagaa	gttctagacc	1020							
cctgcgtgtg	gggtactatg	agactgacaa	ctataccatg	cccagccc	ccatgaggag	1080								
ggctctgata	gagacca	agc	agagacttga	ggctg	ctggc	cacacgctga ttccc	1140							
acccaacaac	atacc	ctac	cc	ctggaggt	cctgt	ctgcg ggcggc	1200							
tggcc	cgagt	ttt	ctccaa	acttcaa	agg	tgactt	gtg	atggagac	1260					
gatcttaatt	ctgagg	ctgc	cc	agctgg	ttt	aaaagactg	ctgag	ccctcc	tgctga	1320				
tctgtt	ccg	ctgg	ccag	c	ctt	ctca	cag	tgcgt	cctcggt	ctgaaa	1380			
gtggaa	actg	cag	catg	aga	tt	gagatgt	ta	cgcc	actgt	gtgat	gtccc	1440		
gatgaactt	g	at	gt	gt	gc	tgc	tgac	ccat	cc	tc	actgtacgg	1500		
ggcagagcc	ac	agg	gg	gct	ac	ac	ctac	ctac	ct	ct	actgc	1560		
gggggtgg	tg	ctgt	ccac	ca	ct	gt	cc	cc	cc	cc	ctac	1620		
aggctactt	ggg	gat	at	ct	ct	cat	c	c	c	c	at	actgtcg	1680	
tctgc	ctgt	gt	gt	gc	ag	ct	gt	ct	cc	cc	tt	gt	1740	
catgc	ggg	g	tg	ga	ac	ac	gc	tg	cc	cc	cc	tt	cat	1800
ccgc	ccag	ctc	tg	gg	ac	cc	ct	gt	cc	cc	cc	tt	cc	1860
agccaccacc	cac	cg	gg	gg	cc	cc	cc	cc	cc	cc	cc	cc	cc	1920
gactc	cct	gc	cc	ca	cac	cc	cc	cc	cc	cc	cc	cc	cc	1980
tgat	cc	ct	ttt	at	tt	tt	tt	tt	tt	tt	tt	tt	tt	2040
caaaaacaat	gc	gt	ttt	at	ttt	ct	tt	tt	tt	tt	tt	tt	tt	2100
gct	ggg	aa	gg	gg	gg	gg	gg	gg	gg	gg	gg	gg	gg	2160
aagg	cct	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	2220
tc	ct	gt	cc	tt	tt	tt	tt	tt	tt	tt	tt	tt	tt	2280
tc	c	ct	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	2340
gt	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	cc	2400
gaga	ca	gg	ct	gg	cc	cc	cc	cc	cc	cc	cc	cc	cc	2460
gctt	ca	ac	ca	ag	gt	cc	cc	cc	cc	cc	cc	cc	cc	2472
aaaaaaa	aa													

<210> 6  
<211> 579  
<212> PRT

<3> *rattus rattus*

&lt;400&gt; 6

Met Val Leu Ser Glu Val Trp Thr Thr Leu Ser Gly Val Ser Gly Val  
1 5 10 15Cys Leu Ala Cys Ser Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr  
20 25 30Gly Arg Gln Lys Ala Arg Gly Ala Ala Thr Arg Ala Arg Gln Lys Gln  
35 40 45Arg Ala Ser Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu  
50 55 60Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Thr Leu Pro Leu Leu  
65 70 75 80Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val  
85 90 95Phe Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
100 105 110Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala  
115 120 125Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
130 135 140Phe Ser Tyr Lys Gly His Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu  
145 150 155 160Gly Met Pro Ser Glu Ser Asp Cys Val Val Val Gln Val Leu Lys Leu  
165 170 175Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu  
180 185 190Ser Phe Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp  
195 200 205Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro  
245 250 255Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly  
260 265 270

Gln Thr Ala Val Gln Leu Ser Leu Gly Pro Met Ala Arg Asp Val Glu  
 275 280 285

Ser Leu Ala Leu Cys Leu Lys Ala Leu Leu Cys Glu His Leu Phe Thr  
 290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Arg  
 305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
 325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Leu Ile Glu Thr Lys Gln Arg  
 340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Asn Asn Ile  
 355 360 365

Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly  
 370 375 380

Gly Arg Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
 385 390 395 400

Leu Gly Asp Leu Ile Leu Ile Leu Arg Leu Pro Ser Trp Phe Lys Arg  
 405 410 415

Leu Leu Ser Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe  
 420 425 430

Leu Asn Ser Met Arg Pro Arg Ser Ala Glu Lys Leu Trp Lys Leu Gln  
 435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala  
 450 455 460

Met Asn Leu Asp Val Leu Leu Thr Pro Met Leu Gly Pro Ala Leu Asp  
 465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu  
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
 500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu Leu Tyr Lys Gly Tyr Phe Gly  
 515 520 525

Asp Ile Trp Asp Ile Ile Leu Lys Lys Ala Met Lys Asn Ser Val Gly  
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Gln Leu Met Thr Pro Gln Lys  
 565 570 575

Gln Pro Ser

<210> 7  
 <211> 2063  
 <212> DNA  
 <213> homo sapiens

<400> 7	
tgccggccgg taggcagcag caggctgaag ggatcatggt gcagtacgag ctgtggccg	60
cgcgtccctgg cgcctccggg gtcgcctcgg cctgtctgtt cgtggccggc gccgtggccc	120
tgcgctggtc cgggcgcggg acggcgcggg gcgcggtggt ccgggcgcga cagaaggcagc	180
gagcgggcct ggagaacatg gacaggcggg cgcagcgctt ccggctccag aacccagacc	240
tggactcaga ggcgctgcta gcccgtcccc tgcctcagct ggtgcagaag ttacacagta	300
gagagctggc ccctgaggcc gtgctttca cctatgtggg aaaggcctgg gaagtgaaca	360
aagggaccaa ctgtgtgacc tcctatctgg ctgactgtga gactcagctg tctcaggccc	420
caaggcaggg cctgctctat ggcgtccctg tgagcccaa ggagtgcctc acctacaagg	480
gccaggactc cacgctggc ttgagcctga atgaagggtt gcccggag tgcgacagcg	540
tagtggtgca tgcgtgttgc ctcgtccctt cgtgcacacc aatgttccac	600
agtccatgtt cagctatgac tgcagtaacc ccctcttgg ccagaccgtg aacccatgga	660
agtccctcaa aagcccaggg ggctcctcag ggggtgaagg ggccctcatac gggctggag	720
gctcccccctt ggcttaggc actgatatcg gaggcagcat ccgcttcccc tcctccttct	780
gcccgcattc cggcctcaag cccacaggaa accgcctcag caagagtggc ctgaagggt	840
gtgtctatgg acaggaggca gtgcgtctct ccgtggccccc catggccgg gacgtggaga	900
gcctggact gtgcctgcga gcccgtctgt gcgaggacat gttccgcctt gacccactg	960
tgcctccctt gcccctcaga gaagaggctt acaccagctc tcagccctt cgtgtgggt	1020
actatgagac tgacaactat accatgcctt cccggccat gaggcggcc gtgctggaga	1080
ccaaacagag cttttaggct gcggggcaca cgctggttcc ttcttgcac agcaacatac	1140
cccatgctctt ggagaccctt tcaacagggtt ggcttccatg tgcgtggc cacacccatc	1200
tacagaactt caaagggtat ttgcgtggacc cctgcctggg ggacccgttca tcaattctga	1260
agcttccca atggctaaa ggactgtgg cttccctggt gaaggctctg ctggcaaggc	1320
tgcagctt cctcagcaac atgaagtctc gtgcgtggaaa aactctgg gaactgcagc	1380
acgagatcga ggtgtaccgc aaaaccgtga ttgcggcgtt gaggcgcgtt gacccgtt	1440
tggcgttgcac cccatgctt gcccgtctt tggacttgaat gcccaggc agggccacag	1500
ggccgttgcac ctacactatg ctgtacaact gcctggactt ccctgcagggtt gtcgtggc	1560
tcaccacgggtt gactgttgcag gacgaggccc agatggaaaca ttacaggggc tacccgggg	1620
atatctggga caagatgttgc cagaaggcata tgaagaagat gtcgtggcgtt ccggccggc	1680

tgcagtgtgt ggctctgccc tggcaagaag agttgtgtct gcggttcatg cgggagggtgg	1740
agcgaactgat gaccctgaa aagcagtcat cctgatggct ctggctccag aggacctgag	1800
actcacactc tctgcagccc agcctagtca gggcacagct gcctgtctgc cacagcaagg	1860
aaatgtcctg catggggcag aggcttcgtgtccttc ccaacccct gcaagaagcg	1920
ccgactccct gagtctggac ctccatccct gctctggtcc cctctttcg tcctgtatccc	1980
tccaccccca tgtggcagcc catgggtatg acataggcca aggcccaact aacagtcaag	2040
aaacaaaaaaaaaaa aaa	2063

<210> 8  
<211> 579  
<212> PRT  
<213> homo sapiens

<400> 8

Met Val Gln Tyr Glu Leu Trp Ala Ala Leu Pro Gly Ala Ser Gly Val  
1 5 10 15

Ala Leu Ala Cys Cys Phe Val Ala Ala Ala Val Ala Leu Arg Trp Ser  
20 25 30

Gly Arg Arg Thr Ala Arg Gly Ala Val Val Arg Ala Arg Gln Lys Gln  
35 40 45

Arg Ala Gly Leu Glu Asn Met Asp Arg Ala Ala Gln Arg Phe Arg Leu  
50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Pro  
65 70 75 80

Gln Leu Val Gln Lys Leu His Ser Arg Glu Leu Ala Pro Glu Ala Val ,  
85 90 95

Leu Phe Thr Tyr Val Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
100 105 110

Cys Val Thr Ser Tyr Leu Ala Asp Cys Glu Thr Gln Leu Ser Gln Ala  
115 120 125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
130 135 140

Phe Thr Tyr Lys Gly Gln Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu  
145 150 155 160

Gly Val Pro Ala Glu Cys Asp Ser Val Val Val His Val Leu Lys Leu  
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe  
180 185 190

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe  
180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Val Asn Pro Trp  
 195 200 205

Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
 210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
 225 230 235 240

Ser Ile Arg Phe Pro Ser Ser Phe Cys Gly Ile Cys Gly Leu Lys Pro  
 245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly  
 260 265 270

Gln Glu Ala Val Arg Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu  
 275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg  
 290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Thr  
 305 310 315 320

Ser Ser Gln Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
 325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Val Leu Glu Thr Lys Gln Ser  
 340 345 350

Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Ser Asn Ile  
 355 360 365

Pro His Ala Leu Glu Thr Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly  
 370 375 380

Gly His Thr Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
 385 390 395 400

Leu Gly Asp Leu Val Ser Ile Leu Lys Leu Pro Gln Trp Leu Lys Gly  
 405 410 415

Leu Leu Ala Phe Leu Val Lys Pro Leu Leu Pro Arg Leu Ser Ala Phe  
 420 425 430

Leu Ser Asn Met Lys Ser Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln  
 435 440 445

His Glu Ile Glu Val Tyr Arg Lys Thr Val Ile Ala Gln Trp Arg Ala  
 450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ala Pro Ala Leu Asp  
 465 470 475 480

60420065 .102102

Leu Asn Ala Pro Gly Arg Ala Thr Gly Ala Val Ser Tyr Thr Met Leu  
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Arg Gly Tyr Phe Gly  
515 520 525

Asp Ile Trp Asp Lys Met Leu Gln Lys Gly Met Lys Lys Ser Val Gly  
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys  
565 570 575

Gln Ser Ser